Physician profile
Rajinder Kaur
NPI 1811624695
$3,468.75
in general payments reported to CMS, 2019-2025
23 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $138 · 2023: $2,599 · 2024: $562 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904 · Education: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.91 |
| Education | $427.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,120.41 | 2022-2025 | Cabometyx |
| Astellas Pharma US INC | $218.98 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $185.47 | 2022-2025 | |
| Abbvie INC. | $148.97 | 2023-2025 | |
| Lilly USA, LLC | $124.87 | 2023 | Verzenio, Jaypirca |
| Daiichi Sankyo INC. | $113.52 | 2023-2024 | Injectafer, Enhertu |
| Incyte Corporation | $112.52 | 2023-2024 | Jakafi |
| Celgene Corporation | $51.85 | 2023-2024 | Reblozyl |
| Stemline Therapeutics INC. | $46.00 | 2023 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $45.55 | 2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $40.67 | 2023-2024 | Fruzaqla, Ninlaro |
| Pharmaessentia USA Corporation | $36.60 | 2023-2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $30.59 | 2023 | Ultomiris |
| Merck Sharp & Dohme LLC | $23.72 | 2023 | Keytruda |
| Amgen INC. | $22.83 | 2023 | Xgeva, Vectibix, Nplate |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.31 | 2024 | |
| Sobi, INC | $20.59 | 2023 | |
| Beigene USA, INC. | $20.20 | 2024 | Brukinsa |
| Janssen Biotech, INC. | $18.87 | 2023 | |
| Genmab U.S., INC. | $18.51 | 2023 | Epkinly |
| Seagen INC. | $16.19 | 2023 | Padcev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.67 | 2023 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.